Therapeutic peptides: current applications and future directions
L Wang, N Wang, W Zhang, X Cheng, Z Yan… - Signal transduction and …, 2022 - nature.com
Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …
production, modification, and analytic technologies. Peptides have been produced and …
The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
WF Garcia-Beltran, KJS Denis, A Hoelzemer, EC Lam… - Cell, 2022 - cell.com
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
[HTML][HTML] Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase …
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)
M Cascella - 2020 - ncbi.nlm.nih.gov
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
Homologous and heterologous Covid-19 booster vaccinations
RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …
have received emergency use authorization in the United States are highly effective …
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …
[HTML][HTML] Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Objective To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE)
against concerned outcomes in real-world settings. Methods Studies reporting COVID-19 VE …
against concerned outcomes in real-world settings. Methods Studies reporting COVID-19 VE …